Farmastela - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 527,537 | 552,589 | 1,912,499 | 6,424,062 | 3,751,845 | 8,136,969 | 12,062,271 | 9,681,713 |
| Profit before tax | - | - | - | 1,708,704 | 1,103,558 | 1,731,352 | 4,447,729 | 3,825,030 |
| Net profit | 463,584 | 412,195 | 595,727 | 1,452,398 | 937,991 | 1,471,575 | 3,780,433 | 3,170,955 |
| Equity | 321,330 | 233,525 | 599,252 | 1,342,650 | 680,641 | 562,216 | 429,060 | 161,171 |
| Liabilities | 100,974 | 73,021 | 632,698 | 383,819 | 105,679 | 1,054,557 | 978,271 | 372,556 |
| Non-current assets | 36,624 | 43,337 | 21,322 | 8,738 | 8,764 | 4,649 | 1,274 | 1,503 |
| Current assets | 385,302 | 380,059 | 1,210,270 | 1,717,529 | 777,463 | 1,611,994 | 1,405,954 | 531,998 |
| Total assets | 421,926 | 423,396 | 1,231,592 | 1,726,267 | 786,227 | 1,616,643 | 1,407,228 | 533,501 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 418,533 | 825,519 | 1,508,120 |
| Social insurance contributions | - | - | - | - | - | 1,747 | 1,921 | 1,183 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +42.8% | +4.7% | +246.1% | +235.9% | -41.6% | +116.9% | +48.2% | -19.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 109.9% | 97.4% | 48.4% | 84.1% | 119.3% | 91.0% | 268.6% | 594.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 144.3% | 176.5% | 99.4% | 108.2% | 137.8% | 261.7% | 881.1% | 1967.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 87.9% | 74.6% | 31.1% | 22.6% | 25.0% | 18.1% | 31.3% | 32.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 26.6% | 29.4% | 21.3% | 36.9% | 39.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.3 | 1.1 | 0.3 | 0.2 | 1.9 | 2.3 | 2.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 263,769 | 276,295 | 620,277 | 2,028,630 | 1,216,828 | 2,569,542 | 3,912,130 | 3,140,049 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Farmastela - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-04-19 | 2022-05-01 | 6.13 |
Farmastela - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-23 | 2026-04-24 | 173.77 |
| 2026-04-15 | 2026-04-20 | 2766.77 |
| 2024-10-02 | 2024-10-16 | 0.36 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Farmastela, UAB (code 303186851) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, the company generated revenue of €9.68M and net profit of €3.17M, with a profit margin of 32.8%. Revenue declined by 19.7% year on year from €12.06M in 2024, but remained above the €8.14M reported in 2023, indicating a two-year increase overall. Net profit followed a similar pattern, rising from €1.47M in 2023 to €3.78M in 2024, then easing to €3.17M in 2025. The balance sheet contracted during the period: total assets decreased to €533.5K in 2025 from €1.41M in 2024 and €1.62M in 2023, while equity fell to €161.2K and liabilities to €372.6K. Debt relative to equity remained elevated at 2.31. Asset turnover was very high at 18.15x, and revenue per employee reached €3.23M, reflecting strong operating output relative to the reported workforce base.